Given the favorable biocompatibility, safety profile, and delivery efficiency of UTMD technology, the combined therapeutic approach of melatonin with RORα/cationic microbubbles may represent a promising strategy for managing sepsis-induced cardiomyopathy (65). The gene discussed is RORA; the disease is Sepsis.